Ireland
--:--IST
Latest
Clinical Trials in Canada / NCT06548399
Recruiting Observational

Longitudinal Study on Bacterial Production of LPC and LPA in Patients With Inflammatory Bowel Disease

NCT06548399 · tracked via the Priya Life Science Canada tracker
Phase
Observational
Started
2024-12-01
Last updated
2026-10-01

Condition(s) studied

Inflammatory Bowel DiseasesCrohn's DiseaseUlcerative Colitis

Study summary

The purpose of this study is to investigate whether the gut bacteria in IBD patients cause ongoing abdominal pain, even when the disease is calm. Many inflammatory bowel disease (IBD) patients have this pain, regardless of whether their disease is active or not. This might be linked to an imbalance in gut bacteria. Certain IBD patients with persistent abdominal pain experience increased sensitivity in their gut due to bacteria producing LPC and LPA. Our goal is to explore the connection between bacterial LPC/LPA levels and symptoms in IBD patients with long-lasting abdominal pain. Additionally, we aim to pinpoint the specific bacteria responsible for producing LPC/LPA, which in turn causes chronic abdominal pain in these patients.

Eligibility

Sex
ALL
Min age
18 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria: * 18 and 70 years of age * Crohn's disease diagnosis with history of past or current moderate or severe chronic abdominal pain that persist despite colitis being in remission (absence of overt inflammation on CT or MRI imaging, and baseline fecal calprotectin of less than 200 μg/g of stool), or in presence of mild inflammation defined by colonoscopy (Simple Endoscopic Score for Crohn's Disease score: 0-10), * Ulcerative colitis diagnosis with history of past or current moderate or severe chronic abdominal pain that persist despite colitis being in remission (absence of overt inflammation on CT or MRI imaging, and baseline fecal calprotectin less than 200 μg/g of stool) or in presence of mild inflammation defined by colonoscopy (Endoscopic Mayo score: 0-1) Exclusion Criteria: * Current acid anti-secretory and antacid medications * Antibiotics, antibacterial agents or probiotics, currently, or within the last 8 weeks * Current pain treatment with opioids or NSAIDs (acetaminophen is permitted) * Alcohol or drug abuse * Concurrent systemic disease and/or laboratory abnormalities considered by investigators to be a risk or that could interfere with data collection

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
McMaster University Hamilton Ontario Recruiting

More McMaster University trials in Canada

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06548399 on ClinicalTrials.gov ↗ ← All trials in Canada